US EditionPublished • loading... • Updated
ABL Bio Receives Upfront Payment for License, Research and Collaboration Agreement for Grabody Platform and Equity Investment from Lilly
ABL Bio secured $55 million from Lilly to accelerate R&D on its Grabody bispecific antibody platform targeting obesity and muscle disorders, part of a $2.6 billion deal.
- On Dec. 25, 2025, ABL Bio, Inc. announced it will receive a USD 40 million upfront payment and a USD 15 million equity investment from Eli Lilly and Company, securing USD 55 million in near-term R&D funding.
- Using the funding, ABL Bio will accelerate R&D on the Grabody bispecific platform, bispecific ADCs and dual-payload ADCs, and expand Grabody indications into obesity and muscle disorders.
- Regulatory progress includes ABL001 receiving FDA Fast Track designation, and ABL111 , co-developed with NovaBridge, presented encouraging Phase 1b data at ESMO GI 2025.
- ABL Bio and Eli Lilly and Company are now conducting joint R&D on multiple therapeutic candidates leveraging the Grabody platform and exploring broad long-term collaborative opportunities.
- On November 12 and 14, ABL Bio signed agreements with Eli Lilly and Company valued at USD 2.602 billion, framing a long-term collaboration beyond the immediate cash package.
Insights by Ground AI
43 Articles
43 Articles
The Berkshire Eagle+42 Reposted by 42 other sources
ABL Bio Receives Upfront Payment for License, Research and Collaboration Agreement for Grabody Platform and Equity Investment from Lilly
Secured a total of 55 million in R&D funding, including 40 million in upfront payment and 15 million in equity investment
Coverage Details
Total News Sources43
Leaning Left7Leaning Right6Center16Last UpdatedBias Distribution55% Center
Bias Distribution
- 55% of the sources are Center
55% Center
L 24%
C 55%
R 21%
Factuality
To view factuality data please Upgrade to Premium
